Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
机构:[1]National Cancer Center, State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China[2]Hunan Cancer Hospital, Changsha, People’s Republic of China[3]First Affiliated Hospital, Jilin University, Changchun, People’s Republic of China[4]The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People’s Republic of China[5]Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China[6]Cancer Center of Hebei Province and The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China河北医科大学第四医院[7]Peking University Cancer Hospital and Institute, Beijing, People’s Republic of China[8]Tongji Hospital, Huazhong University of Science and Technology, Wuhan, People’s Republic of China华中科技大学同济医学院附属同济医院[9]Jiangsu Cancer Hospital, Nanjing, People’s Republic of China[10]Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China[11]Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China[12]Jiangsu Hengrui Medicine, Shanghai, People’s Republic of China
PURPOSEPyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study.PATIENTS AND METHODSChinese patients with HER2-positive relapsed or metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400 mg pyrotinib or lapatinib 1,250 mg orally once per day for 21-day cycles in combination with capecitabine (1,000 mg/m(2) orally twice per day on days 1 to 14). The primary end point was investigator-assessed overall response rate per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.RESULTSBetween May 29, 2015, and March 15, 2016, 128 eligible patients were randomly assigned to the pyrotinib (n = 65) or lapatinib (n = 63) treatment groups. The overall response rate was 78.5% (95% CI, 68.5% to 88.5%) with pyrotinib and 57.1% (95% CI, 44.9% to 69.4%) with lapatinib (treatment difference, 21.3%; 95% CI, 4.0% to 38.7%; P = .01). The median progression-free survival was 18.1 months (95% CI, 13.9 months to not reached) with pyrotinib and 7.0 months (95% CI, 5.6 to 9.8 months) with lapatinib (adjusted hazard ratio, 0.36; 95% CI, 0.23 to 0.58; P < .001). The most frequent grade 3 to 4 adverse events were hand-foot syndrome in 16 of 65 patients (24.6%) in the pyrotinib group versus 13 of 63 (20.6%) in the lapatinib group; diarrhea in 10 patients (15.4%) versus three patients (4.8%), respectively; and decreased neutrophil count in six patients (9.2%) versus two patients (3.2%), respectively.CONCLUSIONIn women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial.
基金:
Jiangsu Hengrui Medicine; CAMS Initiative for Innovative Medicine [2017-12M-3-004, CAMS-12M-1-010]; National Science and Technology Major Project of the Ministry of Science and Technology, China [2015ZX0910100703, 2015ZX0910100704]
第一作者机构:[1]National Cancer Center, State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
通讯作者:
通讯机构:[*1]Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan South Ln, Chaoyang District, Beijing, 100021, People’s Republic of China
推荐引用方式(GB/T 7714):
Fei Ma,Quchang Ouyang,Wei Li,et al.Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(29):2610-+.doi:10.1200/JCO.19.00108.
APA:
Fei Ma,Quchang Ouyang,Wei Li,Zefei Jiang,Zhongsheng Tong...&Binghe Xu.(2019).Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.JOURNAL OF CLINICAL ONCOLOGY,37,(29)
MLA:
Fei Ma,et al."Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study".JOURNAL OF CLINICAL ONCOLOGY 37..29(2019):2610-+